Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Nov;41(11):2484–2491. doi: 10.1128/aac.41.11.2484

Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.

N K Back 1, B Berkhout 1
PMCID: PMC164149  PMID: 9371354

Abstract

The nucleoside drug lamivudine (3TC) triggers the selection of resistant forms of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) with a substitution of amino acid 184Met. The 3TC-resistant RT enzymes 184Val and 184Ile exhibit a processivity defect in in vitro assays that correlates with reduced replication of the corresponding virus variants in primary cells. However, no replication defect is apparent for these two mutants in the transformed T-cell line SupT1. One obvious difference between the two cell types is the intracellular deoxynucleoside triphosphate (dNTP) level. Primary cells have a much smaller dNTP pool, and this cellular condition may emphasize the processivity defect of the codon 184 RT variants. Alternatively, cell-specific cofactors that influence the process of reverse transcription may exist. Such accessory factors may be packaged into the virion to exert an effect on the RT enzyme. To discriminate between these possibilities we performed additional assays with the wild-type and mutant RT enzymes. The RT proteins were either isolated from virions produced by primary and transformed cell types or expressed as recombinant protein. We also performed infection assays with cells treated with a drug that reduces the intracellular dNTP pool. Furthermore, reverse transcription was studied within virus particles in the endogenous assay, which allows for the manipulation of the dNTP level. The combined results indicate that the enzymatic defect of the 3TC-resistant HIV-1 variants is stressed at low dNTP concentrations.

Full Text

The Full Text of this article is available as a PDF (4.8 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arts E. J., Mak J., Kleiman L., Wainberg M. A. DNA found in human immunodeficiency virus type 1 particles may not be required for infectivity. J Gen Virol. 1994 Jul;75(Pt 7):1605–1613. doi: 10.1099/0022-1317-75-7-1605. [DOI] [PubMed] [Google Scholar]
  2. Back N. K., Nijhuis M., Keulen W., Boucher C. A., Oude Essink B. O., van Kuilenburg A. B., van Gennip A. H., Berkhout B. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 1996 Aug 1;15(15):4040–4049. [PMC free article] [PubMed] [Google Scholar]
  3. Bakhanashvili M., Avidan O., Hizi A. Mutational studies of human immunodeficiency virus type 1 reverse transcriptase: the involvement of residues 183 and 184 in the fidelity of DNA synthesis. FEBS Lett. 1996 Aug 12;391(3):257–262. doi: 10.1016/0014-5793(96)00747-8. [DOI] [PubMed] [Google Scholar]
  4. Balzarini J., Pelemans H., Karlsson A., De ClercQ E., Kleim J. P. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13152–13157. doi: 10.1073/pnas.93.23.13152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Berkhout B., van Wamel J. L. Role of the DIS hairpin in replication of human immunodeficiency virus type 1. J Virol. 1996 Oct;70(10):6723–6732. doi: 10.1128/jvi.70.10.6723-6732.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boucher C. A., Cammack N., Schipper P., Schuurman R., Rouse P., Wainberg M. A., Cameron J. M. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993 Oct;37(10):2231–2234. doi: 10.1128/aac.37.10.2231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Boyer P. L., Hughes S. H. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1995 Jul;39(7):1624–1628. doi: 10.1128/aac.39.7.1624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Coates J. A., Cammack N., Jenkinson H. J., Jowett A. J., Jowett M. I., Pearson B. A., Penn C. R., Rouse P. L., Viner K. C., Cameron J. M. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother. 1992 Apr;36(4):733–739. doi: 10.1128/aac.36.4.733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Coates J. A., Cammack N., Jenkinson H. J., Mutton I. M., Pearson B. A., Storer R., Cameron J. M., Penn C. R. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother. 1992 Jan;36(1):202–205. doi: 10.1128/aac.36.1.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Coffin J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483–489. doi: 10.1126/science.7824947. [DOI] [PubMed] [Google Scholar]
  11. Collin M., Gordon S. The kinetics of human immunodeficiency virus reverse transcription are slower in primary human macrophages than in a lymphoid cell line. Virology. 1994 Apr;200(1):114–120. doi: 10.1006/viro.1994.1169. [DOI] [PubMed] [Google Scholar]
  12. Fan N., Rank K. B., Slade D. E., Poppe S. M., Evans D. B., Kopta L. A., Olmsted R. A., Thomas R. C., Tarpley W. G., Sharma S. K. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry. 1996 Jul 30;35(30):9737–9745. doi: 10.1021/bi9600308. [DOI] [PubMed] [Google Scholar]
  13. Gao Q., Gu Z., Parniak M. A., Cameron J., Cammack N., Boucher C., Wainberg M. A. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother. 1993 Jun;37(6):1390–1392. doi: 10.1128/aac.37.6.1390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gao W. Y., Cara A., Gallo R. C., Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8925–8928. doi: 10.1073/pnas.90.19.8925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gao W. Y., Johns D. G., Chokekuchai S., Mitsuya H. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8333–8337. doi: 10.1073/pnas.92.18.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Giacca M., Borella S., Calderazzo F., Bianchi L. C., D'Agaro P., Rampazzo C., Bianchi V., Reichard P. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro. AIDS Res Hum Retroviruses. 1996 May 20;12(8):677–682. doi: 10.1089/aid.1996.12.677. [DOI] [PubMed] [Google Scholar]
  17. Giacca M., Zanussi S., Comar M., Simonelli C., Vaccher E., de Paoli P., Tirelli U. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J Infect Dis. 1996 Jul;174(1):204–209. doi: 10.1093/infdis/174.1.204. [DOI] [PubMed] [Google Scholar]
  18. Hammer S. M., Katzenstein D. A., Hughes M. D., Gundacker H., Schooley R. T., Haubrich R. H., Henry W. K., Lederman M. M., Phair J. P., Niu M. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996 Oct 10;335(15):1081–1090. doi: 10.1056/NEJM199610103351501. [DOI] [PubMed] [Google Scholar]
  19. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  20. Ji X., Klarmann G. J., Preston B. D. Effect of human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein on HIV-1 reverse transcriptase activity in vitro. Biochemistry. 1996 Jan 9;35(1):132–143. doi: 10.1021/bi951707e. [DOI] [PubMed] [Google Scholar]
  21. Keulen W., Back N. K., van Wijk A., Boucher C. A., Berkhout B. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 1997 Apr;71(4):3346–3350. doi: 10.1128/jvi.71.4.3346-3350.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Keulen W., Nijhuis M., Schuurman R., Berkhout B., Boucher C. Reverse transcriptase fidelity and HIV-1 variation. Science. 1997 Jan 10;275(5297):229–231. [PubMed] [Google Scholar]
  23. Larder B. A., Kemp S. D., Harrigan P. R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995 Aug 4;269(5224):696–699. doi: 10.1126/science.7542804. [DOI] [PubMed] [Google Scholar]
  24. Lori F., Gallo R. C. Hydroxyurea and AIDS: an old drug finds a new application? AIDS Res Hum Retroviruses. 1995 Oct;11(10):1149–1151. doi: 10.1089/aid.1995.11.1149. [DOI] [PubMed] [Google Scholar]
  25. Lori F., Malykh A., Cara A., Sun D., Weinstein J. N., Lisziewicz J., Gallo R. C. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science. 1994 Nov 4;266(5186):801–805. doi: 10.1126/science.7973634. [DOI] [PubMed] [Google Scholar]
  26. Malley S. D., Grange J. M., Hamedi-Sangsari F., Vila J. R. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11017–11021. doi: 10.1073/pnas.91.23.11017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mansky L. M., Temin H. M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995 Aug;69(8):5087–5094. doi: 10.1128/jvi.69.8.5087-5094.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. McKeating J. A., McKnight A., Moore J. P. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol. 1991 Feb;65(2):852–860. doi: 10.1128/jvi.65.2.852-860.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Meyerhans A., Vartanian J. P., Hultgren C., Plikat U., Karlsson A., Wang L., Eriksson S., Wain-Hobson S. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol. 1994 Jan;68(1):535–540. doi: 10.1128/jvi.68.1.535-540.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Moore J. P., McKeating J. A., Weiss R. A., Sattentau Q. J. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 1990 Nov 23;250(4984):1139–1142. doi: 10.1126/science.2251501. [DOI] [PubMed] [Google Scholar]
  31. Nájera I., Holguín A., Quiñones-Mateu M. E., Muñoz-Fernández M. A., Nájera R., López-Galíndez C., Domingo E. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol. 1995 Jan;69(1):23–31. doi: 10.1128/jvi.69.1.23-31.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. O'Brien W. A., Namazi A., Kalhor H., Mao S. H., Zack J. A., Chen I. S. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol. 1994 Feb;68(2):1258–1263. doi: 10.1128/jvi.68.2.1258-1263.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Olmsted R. A., Slade D. E., Kopta L. A., Poppe S. M., Poel T. J., Newport S. W., Rank K. B., Biles C., Morge R. A., Dueweke T. J. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes. J Virol. 1996 Jun;70(6):3698–3705. doi: 10.1128/jvi.70.6.3698-3705.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Oude Essink B. B., Back N. K., Berkhout B. Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase. Nucleic Acids Res. 1997 Aug 15;25(16):3212–3217. doi: 10.1093/nar/25.16.3212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Oude Essink B. B., Das A. T., Berkhout B. HIV-1 reverse transcriptase discriminates against non-self tRNA primers. J Mol Biol. 1996 Nov 29;264(2):243–254. doi: 10.1006/jmbi.1996.0638. [DOI] [PubMed] [Google Scholar]
  36. Pandey V. N., Kaushik N., Rege N., Sarafianos S. G., Yadav P. N., Modak M. J. Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry. 1996 Feb 20;35(7):2168–2179. doi: 10.1021/bi9516642. [DOI] [PubMed] [Google Scholar]
  37. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586. doi: 10.1126/science.271.5255.1582. [DOI] [PubMed] [Google Scholar]
  38. Saravolatz L. D., Winslow D. L., Collins G., Hodges J. S., Pettinelli C., Stein D. S., Markowitz N., Reves R., Loveless M. O., Crane L. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1996 Oct 10;335(15):1099–1106. doi: 10.1056/NEJM199610103351503. [DOI] [PubMed] [Google Scholar]
  39. Schinazi R. F., Chu C. K., Peck A., McMillan A., Mathis R., Cannon D., Jeong L. S., Beach J. W., Choi W. B., Yeola S. Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother. 1992 Mar;36(3):672–676. doi: 10.1128/aac.36.3.672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schooley R. T., Ramirez-Ronda C., Lange J. M., Cooper D. A., Lavelle J., Lefkowitz L., Moore M., Larder B. A., St Clair M., Mulder J. W. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J Infect Dis. 1996 Jun;173(6):1354–1366. doi: 10.1093/infdis/173.6.1354. [DOI] [PubMed] [Google Scholar]
  41. Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis P., Danner S. A., Mulder J., Loveday C., Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995 Jun;171(6):1411–1419. doi: 10.1093/infdis/171.6.1411. [DOI] [PubMed] [Google Scholar]
  42. Schwartz O., Maréchal V., Danos O., Heard J. M. Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol. 1995 Jul;69(7):4053–4059. doi: 10.1128/jvi.69.7.4053-4059.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Smith D. B., Johnson K. S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988 Jul 15;67(1):31–40. doi: 10.1016/0378-1119(88)90005-4. [DOI] [PubMed] [Google Scholar]
  44. Tanchou V., Gabus C., Rogemond V., Darlix J. L. Formation of stable and functional HIV-1 nucleoprotein complexes in vitro. J Mol Biol. 1995 Oct 6;252(5):563–571. doi: 10.1006/jmbi.1995.0520. [DOI] [PubMed] [Google Scholar]
  45. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653–5656. doi: 10.1073/pnas.90.12.5653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Trono D. Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol. 1992 Aug;66(8):4893–4900. doi: 10.1128/jvi.66.8.4893-4900.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wainberg M. A., Drosopoulos W. C., Salomon H., Hsu M., Borkow G., Parniak M., Gu Z., Song Q., Manne J., Islam S. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 1996 Mar 1;271(5253):1282–1285. doi: 10.1126/science.271.5253.1282. [DOI] [PubMed] [Google Scholar]
  48. Wainberg M. A., Salomon H., Gu Z., Montaner J. S., Cooley T. P., McCaffrey R., Ruedy J., Hirst H. M., Cammack N., Cameron J. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS. 1995 Apr;9(4):351–357. [PubMed] [Google Scholar]
  49. Wakefield J. K., Jablonski S. A., Morrow C. D. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J Virol. 1992 Nov;66(11):6806–6812. doi: 10.1128/jvi.66.11.6806-6812.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]
  51. Yoshioka A., Tanaka S., Hiraoka O., Koyama Y., Hirota Y., Ayusawa D., Seno T., Garrett C., Wataya Y. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem. 1987 Jun 15;262(17):8235–8241. [PubMed] [Google Scholar]
  52. Zack J. A., Arrigo S. J., Weitsman S. R., Go A. S., Haislip A., Chen I. S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990 Apr 20;61(2):213–222. doi: 10.1016/0092-8674(90)90802-l. [DOI] [PubMed] [Google Scholar]
  53. Zhang H., Dornadula G., Pomerantz R. J. Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells. J Virol. 1996 May;70(5):2809–2824. doi: 10.1128/jvi.70.5.2809-2824.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES